Vikram Purohit, an analyst from Morgan Stanley, maintained the Hold rating on ACELYRIN, INC. (SLRN – Research Report). The associated price target was lowered to $5.00. Discover top-rated stocks from ...

Morgan Stanley lowered the firm’s price target on Acelyrin (SLRN) to $5 from $6 and keeps an Equal Weight rating on the shares. The firm is updating its model to remove uveitis estimates following the ...

Piper Sandler reduced their price objective on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th.

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

The izokibep trial did not meet its primary endpoint, showing no significant improvement over placebo in treatment failure rates at 24 weeks. ACELYRIN will discontinue internal investment in izokibep ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

Charles Schwab Investment Management Inc.’s holdings in Acelyrin were worth $3,006,000 as of its most recent SEC filing. Other large investors also recently made changes to their positions in ...

Mercyhurst Lakers NCAA Division I i-m December 11, 2024 Mercyhurst Lakers NCAA Division I i-m December 11, 2024 Mercyhurst Lakers NCAA Division I i-m December 11 ...

Google and DeepMind have developed an artificial intelligence-powered chatbot tool called Med-PaLM designed to generate "safe and helpful answers" to questions posed by healthcare professionals ...

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) announced opinions for three biosimilar candidates from Celltrion, including a biosimilar for reference ...